Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.59 USD
Change Today 0.00 / 0.00%
Volume 1.0K
As of 10:10 AM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

nephros inc (NEPH) Snapshot

Open
$0.59
Previous Close
$0.59
Day High
$0.59
Day Low
$0.59
52 Week High
06/2/14 - $1.29
52 Week Low
04/16/14 - $0.35
Market Cap
14.9M
Average Volume 10 Days
5.9K
EPS TTM
$-0.17
Shares Outstanding
25.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEPHROS INC (NEPH)

Related News

No related news articles were found.

nephros inc (NEPH) Related Businessweek News

No Related Businessweek News Found

nephros inc (NEPH) Details

Nephros, Inc., a commercial stage medical device company, develops and sells high performance liquid purification filters in the United States and Europe. It offers ultrafilters for dialysis centers, which filters water or bicarbonate concentrate for use in hemodialysis devices; and clearance of toxins from blood using an alternative method to hemodialysis in patients with chronic renal failure. The company also provides ultrafilters for hospitals and other commercial facilities that filters water for drinking and washing; and individual water treatment devices to produce safe drinking water for soldiers in the military and outdoor recreation field. In addition, it has two products in various stages of development in the hemodiafiltration (HDF) modality to deliver therapy for end stage renal disease patients, which include OLpur MDHDF filter series for HDF therapy; and OLpur H2H, an add-on module designed to allow the common types of hemodialysis machines for use in HDF therapy. The company was founded in 1997 and is headquartered in River Edge, New Jersey.

7 Employees
Last Reported Date: 11/10/14
Founded in 1997

nephros inc (NEPH) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

nephros inc (NEPH) Key Developments

Nephros Provides Update on the Status of Evaluation of its Hemodiafiltration System

Nephros, Inc. has provided an update on the status of an evaluation of its on-line mid-dilution hemodiafiltration system. As previously announced, DaVita Kidney Care, a division of DaVita HealthCare Partners Inc., initiated a product evaluation of the Nephros hemodiafiltration system. In the course of the evaluation, DaVita informed Nephros that they would require additional validation of the system. Nephros and DaVita agreed upon a protocol for the additional validation work which is projected to be completed in approximately 4-6 weeks. Upon satisfactory completion of the additional validation work, it is anticipated that DaVita will continue its evaluation. The details of DaVita's product evaluation remain confidential.

Nephros, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015

Nephros, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 . Venue: Westin St. Francis Hotel, San Francisco, California, United States.

Nephros, Inc. Announces Management Changes

On January 4, 2015, the Board of Directors of Nephros, Inc. appointed Paul A. Mieyal, a member of the Board, to serve as the Acting President, Acting Chief Executive Officer, Acting Chief Financial Officer and Acting Secretary of the company. Dr. Mieyal succeeds John C. Houghton, whose separation of employment as President, Chief Executive Officer and Acting Chief Financial Officer of the Company was effective on January 4, 2015. In addition, Mr. Houghton resigned as a member of the Board, effective on January 4, 2015. The resignation as a member of the Board was not due to any disagreement by or with Mr. Houghton on any matter relating to the Company's operations, policies or practices. Additionally, Daron Evans has been appointed Chairman of the Board. Mr. Evans will continue to serve as Chairman of the Audit Committee. Dr. Mieyal has served as a director of the Company since September 2007. Dr. Mieyal has been a Vice President of Wexford Capital LP since October 2006.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NEPH:US $0.59 USD 0.00

NEPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $68.43 USD +0.41
Fresenius Medical Care AG & Co KGaA €76.37 EUR +0.65
Nikkiso Co Ltd ¥1,082 JPY -13.00
View Industry Companies
 

Industry Analysis

NEPH

Industry Average

Valuation NEPH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEPHROS INC, please visit www.nephros.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.